Device Trial Radar · NCT05094089
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Feb 24, 2023
Primary completion
Jul 31, 2030
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- W.L.Gore & AssociatesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 26, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The SYN 20-01 Study is a non-interventional, prospective, multicenter, multicohort, international, post-market clinical investigation looking into the assessment of GORE® SYNECOR Biomaterial in focused patient populations and in long-term application. Patients with ventral / incisional hernia amenable to hernia mesh repair will be enrolled into two cohorts (US and EU cohort) and followed-up over the period of 60 months.
Conditions
- Hernia, Ventral
- Hernia Incisional
- Hernia Incisional Ventral
Interventions
Hernia repair with meshDevice
Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hernia RecurrenceTime frame: 24 Months
- Hernia RecurrenceTime frame: 60 Months
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Emory Saint Joseph's Hospital
Atlanta, Georgia
Tufts Medical Center
Boston, Massachusetts
Corewell Health
Grand Rapids, Michigan
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.